New drug hopes to stop liver scarring in its tracks
Disease control
Recruiting now
This phase 2 trial tests a drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) caused by fatty liver disease (MASH). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to check safety and how the drug moves through …
Phase: PHASE2 • Sponsor: Boston Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC